12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Kyprolis carfilzomib: Completed Phase III enrollment

Onyx completed enrollment of about 300 patients in the open-label, European Phase III FOCUS trial evaluating 20 and 27 mg/m 2 IV carfilzomib vs. best supportive care consisting of low-dose steroids plus cyclophosphamide in patients who received >=3 prior treatments. In April 2011, Onyx amended the FOCUS trial, which is designed to support an MAA submission in Europe, to increase patient enrollment to...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >